GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Revenio Group Oyj (OHEL:REG1V) » Definitions » Sloan Ratio %

Revenio Group Oyj (OHEL:REG1V) Sloan Ratio % : 7.00% (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Revenio Group Oyj Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Revenio Group Oyj's Sloan Ratio for the quarter that ended in Mar. 2024 was 7.00%.

As of Mar. 2024, Revenio Group Oyj has a Sloan Ratio of 7.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Revenio Group Oyj Sloan Ratio % Historical Data

The historical data trend for Revenio Group Oyj's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revenio Group Oyj Sloan Ratio % Chart

Revenio Group Oyj Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.52 -0.24 7.51 0.49 10.35

Revenio Group Oyj Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.01 1.59 3.65 10.28 7.00

Competitive Comparison of Revenio Group Oyj's Sloan Ratio %

For the Medical Devices subindustry, Revenio Group Oyj's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revenio Group Oyj's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Revenio Group Oyj's Sloan Ratio % falls into.



Revenio Group Oyj Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Revenio Group Oyj's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(19.109-10.862
--5.975)/137.413
=10.35%

Revenio Group Oyj's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(18.509-15.262
--6.475)/138.9
=7.00%

Revenio Group Oyj's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was 3.2 (Jun. 2023 ) + 4.5 (Sep. 2023 ) + 7.209 (Dec. 2023 ) + 3.6 (Mar. 2024 ) = €18.51 Mil.
Revenio Group Oyj's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -0.2 (Jun. 2023 ) + 5.6 (Sep. 2023 ) + 5.262 (Dec. 2023 ) + 4.6 (Mar. 2024 ) = €15.26 Mil.
Revenio Group Oyj's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -1.1 (Jun. 2023 ) + -3.1 (Sep. 2023 ) + -1.275 (Dec. 2023 ) + -1 (Mar. 2024 ) = €-6.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revenio Group Oyj  (OHEL:REG1V) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Revenio Group Oyj has a Sloan Ratio of 7.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Revenio Group Oyj Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Revenio Group Oyj's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Revenio Group Oyj (OHEL:REG1V) Business Description

Traded in Other Exchanges
Address
Ayritie 22, Vantaa, FIN, 01510
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective and easy-to-use health tech-related screening devices for the detection of diseases of significance to public health. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), perimeter and fundus imaging devices under the iCare brand. Its eye care software platform Oculo offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company's geographical segments include Finland, Other Europe, and Others.

Revenio Group Oyj (OHEL:REG1V) Headlines

No Headlines